MeSH term
Frequency | Condition_Probility | Aged | 27 | 0.0 |
Aged, 80 and over | 12 | 0.0 |
Female | 71 | 0.0 |
Humans | 281 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Animals | 81 | 0.0 |
Gene Expression | 8 | 0.0 |
Acute Disease | 8 | 0.0 |
Adult | 52 | 0.0 |
Chronic Disease | 4 | 0.0 |
*Kidney Transplantation | 2 | 0.0 |
Male | 75 | 0.0 |
Middle Aged | 51 | 0.0 |
*Polymorphism, Genetic | 27 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 98 | 0.0 |
*Tissue Donors | 2 | 1.0 |
Transplantation, Homologous | 2 | 0.0 |
Chemokines/genetics/*metabolism | 4 | 30.0 |
Comparative Study | 24 | 0.0 |
Immunity, Natural | 2 | 0.0 |
Models, Immunological | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 202 | 0.0 |
Mice | 50 | 0.0 |
Microspheres | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
Receptors, Chemokine/*genetics | 46 | 46.0 |
*Chemotaxis, Leukocyte | 3 | 4.0 |
Cytokines/biosynthesis | 3 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Chemotaxis, Leukocyte/*physiology | 5 | 15.0 |
Ligands | 23 | 0.0 |
Molecular Sequence Data | 27 | 0.0 |
Phylogeny | 2 | 0.0 |
RANTES/genetics | 4 | 26.0 |
Reverse Transcriptase Polymerase Chain Reaction | 20 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Cells, Cultured | 47 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Monocyte Chemoattractant Protein-1/analysis/biosynthesis | 2 | 100.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Receptors, Chemokine/*biosynthesis/genetics | 7 | 24.0 |
Time Factors | 15 | 0.0 |
Chemotaxis/drug effects | 5 | 5.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Monocyte Chemoattractant Protein-1/metabolism/pharmacology | 2 | 100.0 |
RNA, Messenger/biosynthesis | 16 | 0.0 |
Receptors, Chemokine/*biosynthesis | 6 | 15.0 |
Cell Movement | 12 | 1.0 |
Chemokines/*physiology | 2 | 6.0 |
Cytokines/pharmacology | 5 | 1.0 |
Receptors, CCR5/*physiology | 2 | 4.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Adolescent | 12 | 0.0 |
Genotype | 36 | 0.0 |
*HIV-1 | 16 | 1.0 |
Haplotypes | 7 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
RNA, Viral/*blood | 2 | 1.0 |
Receptors, CCR5/*genetics | 29 | 17.0 |
Chemokines/*genetics/metabolism | 2 | 33.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Receptors, Chemokine/*genetics/metabolism | 5 | 35.0 |
Statistics | 2 | 0.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
Cell Line | 30 | 0.0 |
Cell Movement/immunology | 3 | 3.0 |
Chemokines/metabolism | 3 | 4.0 |
Immunologic Memory | 7 | 2.0 |
Monocyte Chemoattractant Protein-1/metabolism | 11 | 18.0 |
RANTES/metabolism | 5 | 8.0 |
Receptors, CCR5/metabolism | 9 | 6.0 |
Receptors, Chemokine/metabolism | 10 | 8.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Inflammation/immunology/metabolism/pathology | 3 | 37.0 |
Mice, Inbred C57BL | 11 | 0.0 |
Mice, Knockout | 10 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Phenotype | 10 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Base Sequence | 18 | 0.0 |
Cell Differentiation | 4 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Lymphocyte Activation | 6 | 0.0 |
Receptors, Chemokine/*genetics/*metabolism | 3 | 42.0 |
Tissue Distribution | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
In Vitro | 14 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Antigens, CD14 | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Chemokines/immunology/pharmacology | 2 | 66.0 |
Chemotaxis | 8 | 4.0 |
Receptors, Chemokine/*immunology/metabolism | 2 | 28.0 |
COS Cells | 3 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Flow Cytometry | 28 | 0.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/metabolism | 3 | 3.0 |
Inflammation | 5 | 1.0 |
Monocytes/metabolism | 3 | 0.0 |
Protein Binding | 11 | 0.0 |
Protein Isoforms | 2 | 0.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Signal Transduction | 8 | 0.0 |
Transfection | 15 | 0.0 |
Cell Division/physiology | 3 | 0.0 |
Cell Separation | 3 | 0.0 |
Chemokines/pharmacology | 3 | 9.0 |
Coculture Techniques | 3 | 0.0 |
Fetus | 6 | 1.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 2 | 2.0 |
Up-Regulation | 8 | 0.0 |
Vascular Cell Adhesion Molecule-1/biosynthesis | 2 | 5.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Cholesterol/blood | 3 | 0.0 |
Japan | 4 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Receptors, CCR5/genetics | 11 | 17.0 |
Sequence Deletion | 7 | 0.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
*Membrane Proteins | 3 | 0.0 |
Monocyte Chemoattractant Protein-1/genetics | 3 | 15.0 |
Receptors, Chemokine/genetics | 10 | 21.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Haplotypes/genetics | 3 | 0.0 |
Prognosis | 5 | 0.0 |
Treatment Outcome | 6 | 0.0 |
Anti-HIV Agents/*therapeutic use | 2 | 0.0 |
CD4 Lymphocyte Count | 4 | 0.0 |
Chemokines, CXC/*genetics | 6 | 18.0 |
Disease Progression | 19 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Viral Load | 5 | 0.0 |
Immunohistochemistry | 11 | 0.0 |
Lipopolysaccharides/pharmacology | 7 | 0.0 |
Recombinant Proteins/pharmacology | 8 | 0.0 |
Alleles | 25 | 0.0 |
Chemokines, CC/*metabolism | 6 | 11.0 |
Chemokines, CXC/*metabolism | 2 | 3.0 |
Leukocytes/*immunology | 2 | 1.0 |
Monocytes/immunology | 2 | 0.0 |
Receptors, CCR5/genetics/metabolism | 4 | 15.0 |
Receptors, CXCR4/metabolism | 4 | 2.0 |
Receptors, Chemokine/genetics/*metabolism | 12 | 25.0 |
T-Lymphocytes/immunology | 4 | 0.0 |
Chemotaxis, Leukocyte/*drug effects | 4 | 6.0 |
Drug Synergism | 2 | 0.0 |
Flow Cytometry/methods | 3 | 1.0 |
Tumor Necrosis Factor-alpha/pharmacology | 6 | 0.0 |
Caveolins/metabolism | 2 | 10.0 |
Crosses, Genetic | 2 | 0.0 |
Down-Regulation | 13 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Monocyte Chemoattractant Protein-1/*metabolism | 16 | 51.0 |
Acquired Immunodeficiency Syndrome/*immunology | 2 | 0.0 |
Receptors, CCR5/biosynthesis | 4 | 10.0 |
Enzyme Activation | 4 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Monocyte Chemoattractant Protein-1/*physiology | 8 | 80.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Interferon Type II/pharmacology | 4 | 0.0 |
Interleukin-1/pharmacology | 5 | 0.0 |
Monocyte Chemoattractant Protein-1/biosynthesis | 2 | 8.0 |
Receptors, Chemokine/*analysis | 4 | 11.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Calcium/metabolism | 27 | 1.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Kinetics | 8 | 0.0 |
Chemokines, CXC/pharmacology | 3 | 4.0 |
Chemotaxis/physiology | 2 | 6.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Phosphorylation | 8 | 0.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Cohort Studies | 13 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Models, Animal | 2 | 0.0 |
Aorta/pathology | 2 | 5.0 |
Monocyte Chemoattractant Protein-1/genetics/metabolism | 2 | 20.0 |
Receptors, Chemokine/genetics/metabolism | 2 | 8.0 |
HIV Infections/*genetics/immunology | 2 | 12.0 |
HIV Seropositivity | 2 | 1.0 |
HIV-1 | 2 | 1.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 4 | 1.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Case-Control Studies | 9 | 0.0 |
DNA Primers | 7 | 0.0 |
Polymorphism, Genetic | 14 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Chemokines/*genetics | 5 | 22.0 |
Chemokines, CXC/genetics | 5 | 29.0 |
HIV Seropositivity/genetics | 2 | 40.0 |
Immunity, Natural/genetics | 3 | 4.0 |
Risk Factors | 2 | 0.0 |
Calcium Signaling/immunology | 2 | 9.0 |
Protein Binding/immunology | 2 | 1.0 |
Receptors, CCR5/*metabolism | 4 | 2.0 |
Receptors, Chemokine/*metabolism/physiology | 2 | 33.0 |
Tumor Cells, Cultured | 13 | 0.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Cell Division/drug effects | 3 | 0.0 |
Adoptive Transfer | 2 | 2.0 |
Disease Models, Animal | 2 | 0.0 |
Gene Deletion | 6 | 0.0 |
Receptors, Chemokine/biosynthesis | 4 | 8.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
Binding Sites | 6 | 0.0 |
Chemotaxis, Leukocyte/drug effects | 5 | 6.0 |
Receptors, Chemokine/chemistry/*metabolism | 2 | 40.0 |
Immunization | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Monocytes/*physiology | 5 | 3.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Child | 10 | 0.0 |
Child, Preschool | 4 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Recurrence | 4 | 0.0 |
Gene Frequency | 17 | 0.0 |
Mutation | 8 | 0.0 |
Polymerase Chain Reaction | 15 | 0.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Retrospective Studies | 4 | 0.0 |
Chemokines/*metabolism | 2 | 3.0 |
Naphthoquinones/*pharmacology | 2 | 9.0 |
Dimerization | 3 | 0.0 |
Epitopes | 2 | 0.0 |
Models, Molecular | 5 | 0.0 |
Protein Conformation | 5 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Monocytes/immunology/metabolism | 2 | 4.0 |
Cell Adhesion | 4 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 3 | 0.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Chemotaxis, Leukocyte/immunology | 5 | 8.0 |
Receptors, Chemokine/*metabolism | 15 | 10.0 |
Monocytes/cytology/drug effects | 2 | 5.0 |
Cell Adhesion/immunology | 3 | 1.0 |
Cell Migration Inhibition | 3 | 2.0 |
Cell Movement/*immunology | 5 | 7.0 |
Chemotactic Factors/biosynthesis | 2 | 28.0 |
Monocytes/*immunology/pathology | 2 | 18.0 |
Rats | 5 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
Up-Regulation/immunology | 3 | 1.0 |
Chemotaxis/*drug effects | 5 | 10.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Monocyte Chemoattractant Protein-1/*pharmacology | 6 | 50.0 |
Monocytes/drug effects/metabolism | 4 | 4.0 |
Pertussis Toxin | 2 | 1.0 |
Protein Binding/drug effects | 2 | 0.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Arteriosclerosis/*physiopathology | 2 | 11.0 |
Cell Differentiation/immunology | 3 | 0.0 |
Monocyte Chemoattractant Protein-1/pharmacology | 7 | 33.0 |
Chemokines/*immunology | 4 | 21.0 |
GTP-Binding Protein alpha Subunits, Gi-Go/metabolism | 2 | 5.0 |
Models, Biological | 3 | 0.0 |
Receptors, CCR5/immunology/metabolism | 2 | 18.0 |
Calcium Signaling/drug effects | 3 | 6.0 |
*Chemokines, CC | 5 | 6.0 |
Endocytosis/drug effects | 2 | 3.0 |
Macrophage Inflammatory Protein-1/pharmacology | 2 | 4.0 |
Monocytes/*drug effects | 4 | 7.0 |
RANTES/pharmacology | 7 | 13.0 |
Receptors, Chemokine/*antagonists & inhibitors | 3 | 17.0 |
Monocytes/drug effects/immunology | 2 | 5.0 |
Receptors, Chemokine/immunology/*metabolism | 2 | 20.0 |
Remission, Spontaneous | 2 | 2.0 |
Signal Transduction/*immunology | 3 | 0.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Graft Rejection/*immunology | 2 | 2.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
*Mutation | 4 | 0.0 |
Point Mutation | 3 | 0.0 |
*Cell Movement | 3 | 2.0 |
Chemokines, CC/metabolism | 2 | 4.0 |
Intercellular Signaling Peptides and Proteins/metabolism | 3 | 3.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Receptors, CXCR4/*metabolism | 2 | 1.0 |
Chemokines, CC/*biosynthesis | 2 | 10.0 |
In Situ Hybridization | 3 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Lod Score | 2 | 0.0 |
*Chromosomes, Human, Pair 3 | 4 | 1.0 |
Hybrid Cells | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Mice, SCID | 2 | 0.0 |
Antigen Presentation | 2 | 0.0 |
Dendritic Cells/*immunology/metabolism | 2 | 4.0 |
*Immunity, Cellular | 2 | 1.0 |
Inflammation/immunology | 2 | 1.0 |
Receptors, Chemokine/immunology | 3 | 9.0 |
Interleukin-2/pharmacology | 3 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
RNA, Messenger/drug effects/metabolism | 3 | 2.0 |
Radioligand Assay | 2 | 0.0 |
Chemokines, CC/pharmacology | 2 | 6.0 |
Up-Regulation/*immunology | 2 | 3.0 |
*Cytokines | 8 | 21.0 |
Monocyte Chemoattractant Proteins/pharmacology | 3 | 27.0 |
Receptors, CCR5/analysis | 2 | 4.0 |
Receptors, CXCR4/analysis | 2 | 5.0 |
Cell Movement/drug effects | 5 | 1.0 |
Monocytes/*drug effects/metabolism | 3 | 3.0 |
Binding, Competitive/drug effects | 3 | 4.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Macrophage Inflammatory Protein-1/*metabolism | 3 | 14.0 |
Monocyte Chemoattractant Protein-1/*metabolism/pharmacology | 2 | 100.0 |
*Receptors, Chemokine | 25 | 26.0 |
Receptors, Cytokine/*genetics | 9 | 15.0 |
Sarcoidosis/*genetics | 2 | 12.0 |
Analysis of Variance | 4 | 0.0 |
RNA, Messenger/analysis | 12 | 0.0 |
Receptors, Chemokine/*analysis/genetics | 4 | 50.0 |
Immunity, Cellular | 3 | 0.0 |
Receptors, CCR5/immunology | 2 | 10.0 |
Receptors, Chemokine/*immunology | 4 | 14.0 |
English Abstract | 5 | 0.0 |
Homosexuality, Male | 3 | 3.0 |
Receptors, HIV/genetics | 3 | 30.0 |
Receptors, Cytokine/genetics | 4 | 12.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 2 | 2.0 |
Chemotaxis, Leukocyte | 5 | 2.0 |
Receptors, CCR5/*analysis | 2 | 10.0 |
Umbilical Veins | 2 | 0.0 |
Anti-HIV Agents/*pharmacology | 3 | 2.0 |
Antigens, CD4/metabolism | 2 | 0.0 |
Virus Replication/drug effects | 2 | 0.0 |
Receptors, Interleukin-8B | 5 | 45.0 |
Mitogens/pharmacology | 2 | 0.0 |
Gene Expression Regulation/immunology | 3 | 1.0 |
Cytosol/metabolism | 2 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Lymphocytes/*immunology | 2 | 0.0 |
Cattle | 2 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Monocyte Chemoattractant Proteins/*metabolism | 2 | 50.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Lymphocyte Count | 3 | 0.0 |
CD4-CD8 Ratio | 3 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Receptors, Interleukin/metabolism | 3 | 5.0 |
Cell Movement/physiology | 3 | 1.0 |
Chromosomes, Human, Pair 3/genetics | 2 | 1.0 |
Lipopolysaccharides/*pharmacology | 4 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Receptors, Chemokine/metabolism/*physiology | 2 | 22.0 |
DNA/immunology | 2 | 4.0 |
Leukocytes/immunology | 2 | 1.0 |
Chemokines/*biosynthesis | 2 | 6.0 |
Glomerular Mesangium/*metabolism | 2 | 20.0 |
Astrocytes/*metabolism | 2 | 3.0 |
Macrophage Inflammatory Protein-1/metabolism | 2 | 3.0 |
European Continental Ancestry Group | 2 | 0.0 |
Infant | 4 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
GTP-Binding Proteins/metabolism | 3 | 1.0 |
*Signal Transduction | 5 | 0.0 |
Cricetulus | 3 | 0.0 |
Hamsters | 9 | 0.0 |
Receptors, Cytokine/metabolism | 2 | 2.0 |
Binding, Competitive | 3 | 0.0 |
CHO Cells | 6 | 0.0 |
Receptors, Cytokine/*biosynthesis | 3 | 23.0 |
Homozygote | 4 | 0.0 |
Virus Replication | 4 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Receptors, Lymphocyte Homing/metabolism | 2 | 5.0 |
Receptors, HIV/genetics/*metabolism | 2 | 10.0 |
Aorta | 2 | 1.0 |
Cell Line, Transformed | 2 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Gene Expression/drug effects | 4 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Odds Ratio | 3 | 0.0 |
Immunity, Natural/*genetics | 2 | 12.0 |
Interphase/immunology | 2 | 4.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 2 | 5.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Jurkat Cells | 3 | 0.0 |
Receptors, Chemokine/physiology | 3 | 11.0 |
Receptors, Cytokine/genetics/*physiology | 2 | 22.0 |
Chemokines, CC/*pharmacology | 2 | 9.0 |
Receptors, Chemokine/genetics/physiology | 2 | 40.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
T-Lymphocytes/virology | 3 | 4.0 |
Chemokines/*pharmacology | 3 | 11.0 |
Cytokines/*biosynthesis | 3 | 0.0 |
Chemotaxis, Leukocyte/*immunology | 2 | 4.0 |
Monocyte Chemoattractant Proteins/metabolism | 4 | 44.0 |
Blotting, Western | 4 | 0.0 |
HIV Infections/*genetics/*immunology | 2 | 25.0 |
Proportional Hazards Models | 2 | 0.0 |
Astrocytes/metabolism | 2 | 2.0 |
Glial Fibrillary Acidic Protein/metabolism | 2 | 0.0 |
Virulence | 3 | 1.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
Receptors, Chemokine/*antagonists & inhibitors/physiology | 3 | 42.0 |
Viral Envelope Proteins/*metabolism | 2 | 4.0 |
HIV Infections/*immunology | 2 | 0.0 |
HIV-1/*immunology | 3 | 0.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
HIV-1/*growth & development | 2 | 3.0 |
Macrophages/*physiology | 2 | 2.0 |
Receptors, Cytokine/*metabolism | 2 | 2.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Heterozygote | 4 | 0.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Monocyte Chemoattractant Proteins/*biosynthesis | 2 | 66.0 |
Mycobacterium bovis | 2 | 33.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Macrophages, Alveolar/immunology | 2 | 12.0 |
Th1 Cells/immunology | 2 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Stimulation, Chemical | 2 | 0.0 |
Monocytes/*immunology | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Receptors, CCR5 | 3 | 6.0 |
Survival Analysis | 2 | 0.0 |
HIV-1/*physiology | 2 | 0.0 |
Fibrosis | 2 | 1.0 |
United States/epidemiology | 2 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Gene Library | 2 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Receptors, Chemokine/*antagonists & inhibitors/genetics/metabolism | 2 | 50.0 |
Monocyte Chemoattractant Protein-1/*genetics | 4 | 21.0 |
Pertussis Toxin/pharmacology | 2 | 3.0 |
Receptors, Chemokine/analysis/*biosynthesis | 3 | 75.0 |
Chemokines/biosynthesis/genetics | 2 | 11.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Receptors, Chemokine/*blood | 2 | 33.0 |
Amino Acid Substitution | 2 | 0.0 |
Genes, Reporter | 2 | 0.0 |
RNA/metabolism | 2 | 0.0 |
RANTES/*genetics | 4 | 28.0 |
Statistics, Nonparametric | 3 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/immunology/metabolism | 2 | 4.0 |
Sex Factors | 2 | 0.0 |
Ribonucleases/metabolism | 2 | 1.0 |
Up-Regulation/genetics/immunology | 2 | 3.0 |
*Immunity | 2 | 4.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Monocytes/immunology/*metabolism | 2 | 4.0 |
Monocytes/*metabolism | 2 | 0.0 |
Monocyte Chemoattractant Protein-1/*biosynthesis | 2 | 25.0 |
Cell Division | 3 | 0.0 |
Astrocytes/cytology/drug effects/*metabolism | 2 | 15.0 |
Alzheimer Disease/*genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Valine/genetics | 2 | 2.0 |
